1. Home
  2. AREN vs TNXP Comparison

AREN vs TNXP Comparison

Compare AREN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AREN
  • TNXP
  • Stock Information
  • Founded
  • AREN 2016
  • TNXP 2007
  • Country
  • AREN United States
  • TNXP United States
  • Employees
  • AREN N/A
  • TNXP N/A
  • Industry
  • AREN Medical/Dental Instruments
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • AREN Health Care
  • TNXP Health Care
  • Exchange
  • AREN Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • AREN 64.1M
  • TNXP 71.6M
  • IPO Year
  • AREN N/A
  • TNXP N/A
  • Fundamental
  • Price
  • AREN $1.84
  • TNXP $17.45
  • Analyst Decision
  • AREN
  • TNXP Strong Buy
  • Analyst Count
  • AREN 0
  • TNXP 2
  • Target Price
  • AREN N/A
  • TNXP $585.00
  • AVG Volume (30 Days)
  • AREN 28.2K
  • TNXP 2.6M
  • Earning Date
  • AREN 05-16-2025
  • TNXP 03-18-2025
  • Dividend Yield
  • AREN N/A
  • TNXP N/A
  • EPS Growth
  • AREN N/A
  • TNXP N/A
  • EPS
  • AREN N/A
  • TNXP N/A
  • Revenue
  • AREN $234,396,000.00
  • TNXP $10,094,000.00
  • Revenue This Year
  • AREN $12.73
  • TNXP $84.08
  • Revenue Next Year
  • AREN $71.95
  • TNXP $126.94
  • P/E Ratio
  • AREN N/A
  • TNXP N/A
  • Revenue Growth
  • AREN 45.45
  • TNXP 29.94
  • 52 Week Low
  • AREN $0.56
  • TNXP $6.76
  • 52 Week High
  • AREN $2.18
  • TNXP $672.00
  • Technical
  • Relative Strength Index (RSI)
  • AREN 65.73
  • TNXP 47.53
  • Support Level
  • AREN $1.46
  • TNXP $12.80
  • Resistance Level
  • AREN $1.72
  • TNXP $31.87
  • Average True Range (ATR)
  • AREN 0.12
  • TNXP 4.43
  • MACD
  • AREN 0.02
  • TNXP 0.04
  • Stochastic Oscillator
  • AREN 93.23
  • TNXP 18.58

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about the things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: